Nazzi Gianfranco Form 3/A March 06, 2018

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

À Nazzi Gianfranco

(Last) (First) (Middle)

C/O TEVA

PHARMACEUTICAL

INDUSTRIES LTD., Â 5 BASEL

STREET

(Street)

PETACH TIKVA, L3Â 4951033

(State) (City) (Zip)

1. Title of Security

(Instr. 4)

Statement

(Month/Day/Year)

01/01/2018

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD

10% Owner

[TEVA]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year) 01/02/2018

(Check all applicable)

Commercial

Director

X_ Officer Other (give title below) (specify below) EVP, Growth Markets

6. Individual or Joint/Group

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities

Beneficially Owned

(Instr. 4)

Ownership

Form:

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect

(I)

 $4,245.357 \stackrel{(2)}{=}$

(Instr. 5) D

Â

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

Ordinary Shares (1)

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security**

4. Conversion

5. Ownership

6. Nature of Indirect Beneficial Ownership

or Exercise Form of (Instr. 5)

Edgar Filing: Nazzi Gianfranco - Form 3/A

		(Instr. 4)		Price of	Derivative
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)

Reporting Owners

PETACH TIKVA, L3Â 4951033

	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Nazzi Gianfranco				
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.	Â	Â	EVP, Growth Markets Commercial	Â
5 BASEL STREET			Commercial	

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Gianfranco
Nazzi

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) This Amendment to Form 3 filed on January 2, 2018 is being filed solely to correct the number of Ordinary Shares owned by the Reporting Person.

Â

Remarks:

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign prote: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2